Cell Immunotherapy for Prostate cancer is a promising new approach to treating cancers that otherwise do not respond well to traditional treatments, surgeries, or chemotherapy. The primary goal of all immunotherapies, checkpoint inhibitors, and cancer vaccines is to program the body’s immune system to recognize and eliminate only cancer cells as targets.

Modified Immune Cells to Fight Prostate Cancer

Watch video

T Cell Therapy to Fight Cancer

What is Prostate Cancer?

The prostate is a tubuloalveolar exocrine gland, the size of a ping-pong ball (when healthy). This reproductive gland’s purpose is to produce prostatic fluid, which makes up part of semen. The prostate is located in front of the rectum and below the bladder, around the upper urethral tube that empties urine produced by the bladder. Because of its location, diseases of the prostate affect both sexual function and bladder control. Prostate diseases can be cancerous or noncancerous and can affect blood vessels and peripheral nerves that control erectile function, leading to ED. Prostate cancer (PC) is a medical diagnosis of abnormal cell growth/division (malignancy) in the prostate gland. If left untreated, cancer of the prostate can spread (metastasize) to other areas in the body, including:

Metastasized prostate cancer is considered an advanced form of cancer. Bone is by far the most common site of distant spread, followed by lymph nodes, while spread to the brain is very rare.

Stem Cell Therapy for Prostate Cancer

Immunotherapy for Cancer

Immunotherapy for Cancer

Global Prostate Cancer Statistics

Worldwide, prostate cancer is the second most commonly diagnosed cancer in men. In the United States, it is the most common cancer in men after skin cancer, and current estimates suggest that about 1 in 8 men will be diagnosed with it during their lifetime. Prostate cancer is much more common in men over the age of 50 and is rarely diagnosed in men under 40. In the United States, it is the second leading cause of cancer death in men, behind lung cancer, and about 1 in 44 men will die of it.[1]
Recent Epidemiological studies have shown some distinct geographical and racial distribution for men with prostate cancer and that this disease is more prevalent in Western societies than Asian ones, such as Thailand, where prostate cancer is the 6th leading type of cancer ^[2] The highest rates of prostate cancers were found in Western and Northern European nations such as France and Norway and also in New Zealand, Australia, and North America.

Signs and Symptoms of Prostate Cancer

Early intervention and detection are the key to dealing with Prostate cancer, as the symptoms do not usually show themselves in the very early stages of the disease. PC symptoms vary among men; early symptoms may be caused by other conditions. Early prostate cancer usually causes no symptoms, and routine urine tests do not detect it. For this reason, screening aims to find prostate cancer before symptoms appear. Prostate-specific antigen (PSA) blood tests, sometimes with a digital rectal exam (DRE), are used for screening, and most guidelines advise men from about age 50 to discuss the benefits and risks of screening with their doctor, or earlier if they have a family history of the disease or other higher risk. The symptoms of Prostate cancer often mimic those of other issues, so a small percentage of patients are not diagnosed with prostate cancer until it has metastasized to different areas in the body.

Possible signs and symptoms of prostate cancer, mostly in later stages, include:

Anemia: The patient’s blood does not have enough hemoglobin (healthy red blood cells) due to bone marrow infiltration by the cancerous cells, treatment-related toxic exposure, or androgen deprivation
Severe Abdominal pain: Consistent pressure on the organs surrounding the swollen prostate gland causes soreness and pain in the lower abdomen.
Blood in Semen: Infection or inflammation of the prostate causes blood to appear in the semen
Hematuria (Blood in urine): Cancer in the urinary tract can cause blood to appear in the urine. These symptoms can also occur in patients with kidney failure, kidney cysts, or urinary tract infections.
Issues with incontinence or frequent need to urinate: Enlarged prostate glands due to a tumor near the urethra can cause bladder control issues, urine retention issues, incomplete or trouble starting urination, and a weak stream of urine.
Swelling in the legs: leg swelling can occur when cancer in the pelvic lymph nodes blocks lymph drainage. Sudden swelling of one leg can also be a sign of a blood clot, which needs urgent medical attention.
Frequent fatigue can be caused by traditional chemotherapy or medication-based treatments, depression, or stress that leads to reduced appetite.
Rapid Weight loss can result from side effects of medical treatments that suppress appetite, leading to weight loss.
Spinal compression or Pain in the Lower Lumbar Spine: Sometimes misdiagnosed as Degenerative Disc Disease, pain in the Lower lumbar or hips can occur when cancer spreads to the bone, causing the spinal cord to be compressed, leading to pain

Advanced Symptoms of Prostate Cancer

Patients with late-stage prostate cancer have more complications that lead to much more severe symptoms, primarily when cancer metastasizes to other parts of the body. For example, if prostate cancer metastasizes to the bones, the patients can experience severe bone pain, pressure sensitivity, and fractures easily, like patients who have osteoporosis. Other issues like kidney failure can also occur if the cancer blocks the ureters, the tubes that carry urine from the kidneys to the bladder. Each cancer patient has unique needs and circumstances that lead to advanced symptoms, including factors such as:

Patient’s overall health
Patient age
Family history
Stage of the cancer
Spread of cancer (metastasized) to other areas

Stages of Prostate Cancer

Most urologists describe the spread and growth of prostate cancer in one of 4 stages. Urologists and treatment providers often use the stage of cancer as a guide when offering a prognosis or choosing treatment options. The four stages of Prostate cancer are based on a variety of factors, including screening tests such as:

DRE (digital rectal exam)
Prostate-specific antigen (PSA)
Prostate Biopsies
Imaging tests from MRI scan, CT scan, bone scan, or transrectal ultrasound

To determine the stage of prostate cancer, most urologists around the world start with the “TNM staging system,” which helps define the different aspects of prostate cancer growth.

T – the T component is used to measure the size & extent of the Tumor
N: the N component is used to show whether the prostate cancer has spread to nearby lymph nodes, while spread to Bone and other distant sites is covered by the M component
M – the M component is used to measure if the prostate cancer has spread to any other organs (Metastasized)

Anatomy guide

Prostate and urinary anatomy

A sagittal section through the bladder, prostate and urethra.

1. Bladder: The hollow organ storing urine.
2. Prostate: The gland below the bladder.
3. Urethra: The channel passing through the prostate.
4. Seminal vesicle: A gland behind the bladder.

After a urologist calculates the TNM components, it will often be combined with the Gleason grading system to determine which stage of prostate cancer the patient is currently in. Prostate cancer survival rates are often based on the actual stage and timing of the diagnosis.^[3]

Stage 1 (I) Prostate Cancer
In stage 1, a tumor is usually not detectable by radiology tests or physical exams and has not metastasized outside of the prostate gland. Early discovery of prostate cancer is the key to long-term survival, as the 5-year survival rate for patients with Stage 1 is nearly 100% after five years. Options include active surveillance, which is common for low-risk cancer, external beam radiation therapy, brachytherapy (radiation seeds placed in the prostate), or a radical prostatectomy.
Stage 2 ( IIA and IIB) Prostate Cancer
In Stage 2, a prostate cancer tumor may or may not be detected through radiology scans or a physical examination, but still has not metastasized outside of the prostate gland. Some stage 2 cancers grow faster than stage 1 cancers, and treatment is usually recommended, although active surveillance may suit some lower-risk cases. Treatment options for stage 2 can include radical prostatectomy, sometimes with removal of nearby lymph nodes, external beam radiation therapy with or without short-term hormone therapy, or brachytherapy. Research into prostate cancer immunotherapy for this stage is ongoing, and it is not a standard treatment.
Stage 3 (III) – Prostate Cancer
In Stage 3, the prostate cancer has usually metastasized beyond the prostate gland but has not yet reached the rectum or bladder, and is more likely to return than the earlier stages 1 and 2. Treatment options for Stage 3 include hormone therapy with External beam radiation, external beam plus brachytherapy, Radical prostatectomy, or Immunotherapy for prostate cancer.
Stage 4 (IV) – Prostate Cancer
Stage 4 prostate cancer is the last stage and describes a tumor that has metastasized to other parts of the patient’s body, including the lungs, bones, lymph nodes, liver, or bladder. Survival for stage 4 prostate cancer varies widely with where the cancer has spread and how it responds to treatment, and many men now live for several years with treatment. Treatment for Stage 4 prostate cancer is mainly systemic. Options include hormone therapy (androgen deprivation therapy), often combined with an androgen receptor pathway inhibitor such as abiraterone, enzalutamide, apalutamide or darolutamide, chemotherapy such as docetaxel, radioligand therapy for some patients, PARP inhibitors for men with eligible gene mutations, and radium-223 for some bone metastases. Sipuleucel-T is an approved cellular immunotherapy for some men with metastatic castration-resistant disease, and other forms of Immunotherapy for prostate cancer are being studied in clinical trials. Radiation therapy or a transurethral resection of the prostate (TURP) may be used to relieve symptoms.

Traditional Treatment Options for Prostate Cancer

Currently, the most widely used traditional treatment options for men with prostate cancer are:

Radiation Treatment
Prostate Cancer Surgery
Brachytherapy – Low-dose-rate seed implants and high-dose-rate seed implants
Cryotherapy
Chemotherapy ( metastasized )
Androgen deprivation therapy (ADT) uses hormone blockers such as Casodex (Bicalutamide), Eulexin (Flutamide), Nilandron (Nilutamide), or Lupron.

For patients with slow-growing prostate cancers that are detected early, active surveillance is used to monitor the tumor for any significant (negative) signs. For others, prostate cancer surgeries are usually recommended. Some common laparoscopic or open surgeries include radical prostatectomy or salvage radical prostatectomy for recurrent cases, and can be done by themselves or combined with other treatments such as radiation therapy (Radiotherapy)

Some common types of Radiotherapy include:

Stereotactic high-precision radiosurgery (like CyberKnife)
Intensity-modulated radiation therapy (IG-IMRT)
Stereotactic hypofractionated accelerated radiation therapy (SHARP)

For patients with small, localized (non-metastasized) prostate tumors, non-invasive techniques like partial gland ablation, Cryotherapy, focal therapy, and Brachytherapy can be used to target small areas of the prostate. Still, the recurrence rates are pretty high and may not be the ideal solution to get rid of cancer.

For patients with aggressive prostate cancers, combined treatments are often recommended that include a mix of radiation, brachytherapy, hormone therapy, or external beam therapy to try to reduce the overall adverse effects of radiation exposure.

For high-risk patients or patients where cancer has spread outside the prostate, standard treatment uses systemic therapies such as hormone therapy combined with androgen receptor pathway inhibitors, chemotherapy, radioligand therapy, PARP inhibitors for eligible gene mutations, bone-targeted therapy, and sipuleucel-T, an approved cellular immunotherapy for some men with metastatic castration-resistant disease.

Risks of Prostate Surgery

The Side effects and risks of prostate surgery, like radical prostatectomy, can be high and in line with any major surgery. Problems and risks of surgery can include:

Excessive Bleeding from the surgery
Adverse Reactions to Anesthesia
Damage to surrounding organs
Blood clots in the lungs or legs
Infections near the area of surgery.

Common Side effects of having Prostate Surgery

The significant side effects of having radical prostatectomy surgery include:

Clinical guide

Effects discussed after prostate surgery

The categories listed in the surrounding article text.

Urinary control
Urinary incontinence and changes in bladder control.
Sexual function
Erectile dysfunction and changes in fertility.
Lymphatic swelling
Lymphedema, or swelling associated with lymph fluid.
Hernia
Inguinal hernia is discussed in the article’s list of possible effects.

Urinary incontinence: leakage of urine, which often improves in the months after surgery
Erectile dysfunction, Loss of fertility, and permanent impotence
Lymphedema – swelling caused by a buildup of lymph fluid
An inguinal hernia – retropubic radical prostatectomy (RRP)

Alternative Treatment Option for Prostate Cancer

At the Regeneration Center, our team of experts seeks to provide a well-rounded, integrative approach to the treatment of prostate cancer. Our goal is to offer carefully selected patients, including some with Therapy-Resistant Cancers, investigational biological therapies alongside standard prostate cancer treatment, which remains the foundation of care.[4] These treatment plans are individualized to the patient’s needs, and like all cancer treatments they carry risks, which are discussed with each patient before treatment. Our holistic approach is grounded in functional medicine. It combines supportive approaches and regenerative medicine with conventional treatments for prostate cancer, which remain the foundation of care.

Immunotherapy for Prostate Cancer

Our modern, non-toxic immunotherapy protocols, such as Transurethral Prostate Hyperthermia (TUH), are specifically designed to help restore the body’s defense mechanisms and immune system, enabling them to recognize and destroy cancer cells. The patient’s immune cells are first collected via leukapheresis and then cultured with specific proteins that activate upon reintroduction into the patient’s body and immune system.^[5]

These activated immune cells enhance the body’s natural surveillance against malignant cells, thereby supporting the overall therapeutic approach. The process is conducted in a controlled clinical environment with careful monitoring throughout each phase of treatment.

CAR-T cell therapy for Prostate Cancer

This targeted Immunotherapy for cancer of the prostate is still experimental and is available mainly in clinical trials. CAR-T therapy can cause serious side effects, including cytokine release syndrome and neurotoxicity. Other biological therapies being studied in prostate cancer include:

Anti-angiogenic treatments: these block VEGF signals that help tumors grow new blood vessels, and they are still being studied in prostate cancer
Oncolytic virus therapy (OVT Therapy), This Viral Immunotherapy uses genetically modified viruses to target and kill cancer cells. It is also known as Rigvir Viral Therapy.
Chimeric antigen receptor-engineered T cells ( Car-T Cells) – Uses the patient’s immune cells enhanced in our lab. The CAR T cells are then reintroduced to the patient to target specific proteins and fight prostate cancer.
Dendritic Immunotherapy
Cancer Stem cells
NK Cells – Natural Killer Cell Therapy

Our Approach to Immunotherapy for Prostate Cancer

The Regeneration Center Immunotherapy for Cancer focuses on multiple factors, including the tumor microenvironment, which is pivotal in cancer remission or progression. Research into this integrative functional medical strategy is ongoing, and it has not been proven to improve outcomes in prostate cancer. Browse our website or contact a member of our support team directly to learn more about our cancer immunotherapy protocols, the current evidence behind them, and how they may be used alongside standard treatment.

Our Prostate cancer treatment and research center continues to probe further than ever before. With new discoveries, clinical trials for prostate cancer, and emerging methods of using genetic screening to help guide treatment, we continue to follow research that may improve how prostate cancer is managed.

Stem Cell Treatment for Prostate Cancer in 2026

To determine eligibility and obtain exact prices, along with a day-by-day treatment plan, our oncologists will need to better understand the patient’s current needs based on recent histological results, Biopsies, blood tests, X-rays, or other imaging from the patient’s primary care urologist or oncologist.

If you or a loved one has been diagnosed with prostate cancer, you may wish to learn about investigational immune cell therapies that can be considered alongside standard treatment. Take the first step toward treatment by entrusting your care to our team of experts in our advanced facility. We are here to help. To learn more about our investigational treatment options for prostate cancer and whether they may suit your situation, please contact us today.

Published Clinical Citations

[1] ^ Lojanapiwat, Bannakij, Choosak Pripatnanont, Vorapot Choonhaklai, Surithorn Soontornpun, Supon Sriplakich, Sunai Leewansangtong, Apirak Santi-Ngamkun, et al. 2017. Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand. Prostate international, no. 1 (January 11). doi:10.1016/j.prnil.2017.01.002. https://www.ncbi.nlm.nih.gov/pubmed/28352616

[2] ^ Janiczek, Marlena, Łukasz Szylberg, Anna Kasperska, Adam Kowalewski, Martyna Parol, Paulina Antosik, Barbara Radecka, and Andrzej Marszałek. 2017. Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review. Journal of immunology research (October 3). doi:10.1155/2017/4861570. https://www.ncbi.nlm.nih.gov/pubmed/29109964

[3] ^ Bilusic, Marijo, Ravi A Madan, and James L Gulley. 2017. Immunotherapy of Prostate Cancer: Facts and Hopes. Clinical cancer research : an official journal of the American Association for Cancer Research, no. 22 (June 29). doi:10.1158/1078-0432.CCR-17-0019. https://www.ncbi.nlm.nih.gov/pubmed/28663235

[4] ^ Lojanapiwat, Bannakij. 2015. Urologic cancer in Thailand. Japanese journal of clinical oncology, no. 11 (September 9). doi:10.1093/jjco/hyv125. https://www.ncbi.nlm.nih.gov/pubmed/26355159

[5] ^ Pizzola, Christopher, Syed M Rizvi, and Monika Joshi. 2016. A New Era of Immunotherapy in Prostate Cancer. Current molecular pharmacology, no. 3. https://www.ncbi.nlm.nih.gov/pubmed/26177645

Browse our oncology resource hub for related cancer treatment information.

Immunotherapy & Stem Cells for Treating Prostate Cancer